KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Receivables (2016 - 2025)

Amgen (AMGN) has 17 years of Receivables data on record, last reported at $9.6 billion in Q4 2025.

  • For Q4 2025, Receivables rose 31.04% year-over-year to $9.6 billion; the TTM value through Dec 2025 reached $9.6 billion, up 31.04%, while the annual FY2025 figure was $9.6 billion, 31.04% up from the prior year.
  • Receivables reached $9.6 billion in Q4 2025 per AMGN's latest filing, up from $8.5 billion in the prior quarter.
  • Across five years, Receivables topped out at $9.6 billion in Q4 2025 and bottomed at $4.4 billion in Q1 2021.
  • Average Receivables over 5 years is $6.5 billion, with a median of $6.2 billion recorded in 2022.
  • Peak YoY movement for Receivables: decreased 16.53% in 2021, then soared 31.04% in 2025.
  • A 5-year view of Receivables shows it stood at $5.1 billion in 2021, then grew by 23.8% to $6.3 billion in 2022, then grew by 24.06% to $7.8 billion in 2023, then decreased by 6.01% to $7.3 billion in 2024, then skyrocketed by 31.04% to $9.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $9.6 billion in Q4 2025, $8.5 billion in Q3 2025, and $8.7 billion in Q2 2025.